Relay Therapeutics IncRLAY
Price$18.49

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $10.4M+3.4% YoYTTM through 30 Jun 2026
Net Income -$286MTTM through 30 Jun 2026
Free Cash Flow -$216.5MTTM through 30 Jun 2026

Margins

Current
Operating Margin-2,720.0%
Net Margin-2,763.6%

Returns

-42.5%ROE
-39.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio22.13x
Net Debt-$642.1Mnet cash position
Cash & Equivalents$121.2M

Quality Metrics

Altman Z-Score29.75
Piotroski F-Score2 / 9
FCF Margin-2,092.1%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $15.4M
Diluted EPS-$1.56TTM
'20'21'22'23'24'25
FY2025: $-1.61

Dividend

No dividend

Capital Allocation

Capex Intensity41.8%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.